2000 Sierra Point Parkway
Suite 501
Brisbane, CA 94005
United States
650 484 0899
https://dayonebio.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 155
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Jeremy Bender M.B.A., Ph.D. | CEO, President & Director | 1,05M | N/A | 1971 |
Dr. Samuel C. Blackman M.D., Ph.D. | Co-Founder and Head of R&D | 740,5k | N/A | 1969 |
Mr. Charles N. York II, M.B.A. | COO, CFO & Secretary | 760k | N/A | 1977 |
Mr. Adam Dubow | General Counsel and Chief Compliance Officer | 608,2k | N/A | 1967 |
Dr. Mike Preigh Ph.D. | Chief of Technology Operations | N/A | N/A | N/A |
Ms. Jaa Roberson | Chief People Officer | N/A | N/A | N/A |
Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Development Officer | N/A | N/A | N/A |
Ms. Lauren Merendino M.B.A. | Chief Commercial Officer | N/A | N/A | 1976 |
Dr. Elly Barry M.D. | Chief Medical Officer | N/A | N/A | N/A |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Day One Biopharmaceuticals, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 6, Shareholderrechte: 8, Kompensation: 9.